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Helicobacter pylori (H. pylori) infection is strongly associated with gastric cancer. However, only aminority
of infected individuals ever develop gastric cancer. This risk stratification may be in part due to differences
among strains. The relationship between neutrophil-activating protein (NapA) and gastric cancer is unclear.
The purpose of this study is to evaluate the significance of NapA as a biomarker in gastric cancer. We used
enzyme linked immunosorbent assay (ELISA) to determine the status of H. pylori infection. Indirect ELISA
method was used for detection of NapA antibody titer in the serum of H. pylori infected individuals.
Unconditional logistic regressions were adopted to analyze the variables and determine the association of
NapA and gastric cancer. The results of study indicated serumH. pyloriNapA antibody level were associated
with a reduced risk for development of gastric cancer. Itmay be used in conjugationwith other indicators for
gastric cancer detection.
G
astric cancer is one of the leading types of cancer and the second leading cause of cancer-related death
worldwide, particularly in East Asian populations1–4. It has been calculated that the risk of gastric cancer
in H. pylori-infected individuals is 3 to 6 fold higher than in those who are not infected5. H. pylori, a
Gram-negative bacterium that colonizes the gastric mucosa of humans, has been recognized as the major
etiological agent of chronic gastritis, peptic ulcer disease, and gastric cancer6,7. A number of trials have demon-
strated the possibility of cancer prevention throughH. pylori screening and eradication, particularly in high-risk
populations (thosewith atrophic gastritis, intestinalmetaplasia, dysplasia of the stomach, etc.). In ameta-analysis,
the relative risk of gastric cancer following H. pylori eradication was calculated to be 0.65 overall8. Therefore, its
eradication seems a logical step in the prevention of gastric cancer. However, although more than 50% of the
world population is infected with this bacterium, less than 2%develop gastric cancer2. In screening, the burden for
patients as well as the ethics and the cost-effectiveness need to be taken into consideration. Hence, the strategy of
widespread screening and eradication of H. pylori for gastric cancer seems inappropriate, and the screening of
gastric cancer should be strictly limited to those with established indication ofH. pylori infection. Currently, there
is no sensitive biomarker for H. pylori related gastric cancer detection. Common makers such as CA19-9,
fetoprotein antigen, pepsinogen I/II, and carcinoembryonic antigen (CEA) are prone to a high degree of false
negatives9,10. Therefore, novel markers are urgently required in order to detect H. pylori related gastric cancer.
Moreover, it has been confirmed thatH. pylori related gastric cancer is correlated with various virulence factors of
H. pylori11,12.
H. pylori neutrophil-activating protein (HP-NapA), an important virulence factor that exists in all H. pylori
strains, is associated with adhesion of the bacteria and inflammation occurrence13,14. In addition, NapA antibody
was found more frequently in patients’ sera of H. pylori infection. In the present study, we aim to evaluate the
relationship betweenNapA andH. pylori related gastric cancer and discuss whether it can be used as a simple and
reliable biomarker for the screening and diagnosis of gastric cancer patients.
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Results
Expression and purification of recombinant protein. The gene
encoding for HP-NapA was obtained by PCR amplification using
genomic DNA extracted from H. pylori clinical isolate template. A
435 bp DNA fragment, produced by PCR, was analyzed by agarose
gel electrophoresis. Findings were consistent with expected results,
including napA/pMD-18T detection and confirmation that the napA
gene fragment was 435 bp. After ligating with expression vector
pGEX-4T-1, the recombinant vector napA-pGEX-4T-1 was trans-
formed into E.coli BL21DE3 cells. Nucleotide homology of napA
from H. pylori clinical isolate strains compared with other stan-
dard H. pylori strains on the GenBank was 94% , 98% using the
BioEdit homology search tool.
The recombinant vector napA-pGEX-4T-1 was transformed into
E.coli BL21DE3 cells to express fusion protein NapA, which was
examined by sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE). A pronounced band with an approximatemolecu-
lar weight of 42 kDa appeared in the supernatant of cell lysate after
induction. This band did not appear in control cells, suggesting that
the fusion protein can be successfully expressed in bacterial cells.
Subsequently, the expressed fusion protein NapA was purified with
a GST affinity column. The purified protein was analyzed by SDS-
PAGE, with a purity reaching more than 95% (Supplementary
Fig. S1).
Comparison of Helicobacter pylori infection results. H. pylori
infection in serum samples of gastric cancer cases and controls
were analyzed by an ELISA kit. The main demographic charac-
teristics in study subjects and the detection results of H. pylori
were shown in Table 1. There were no differences in sex and age
between the cases and controls (age, p 5 0.055; sex, p 5 0.055).
Among the 232 cases, 14 (7.22%) were classified as stage I, 16
(8.25%) as stage II, 143 (73.71%) as stage III, and 21 (10.82%) as
stage IV, respectively. Only 9 of 232 patients (3.9%) were gastric
cardia cancer. The seroprevalence of H. pylori was 59.73% (132/
221) in gastric cancer patients, compared with 48.00% (120/250) in
control subjects. The seroprevalence of H. pylori in gastric cancer
patients was significantly higher than the control group (p 5 0.025).
Association between seropositivity ofNapA antibody andGC.The
NapA antibody titer was detected by indirect ELISA in H. pylori
infected populations (132 gastric cancer patients and 120 control
subjects). The results of NapA antibody levels and clinicopatho-
logic factors of the H. pylori-infected individuals were shown in
Table 2. Among the H. pylori seropositivity subjects, NapA seropo-
sitivity was 12.12% (16 of 132) in gastric cancer patients and 1.67% (2
of 120) in controls, respectively. A box plot showed the distribution
of NapA antibody levels of cases and controls infected by H. pylori
(Supplementary Fig. S2). To examine the factors affecting the
relationship between gastric cancer risk and NapA antibody, ORs
(odds ratios) and 95% CIs (confidence intervals) were estimated in
the 252 H. pylori positive cases and control subjects by both
unconditional univariate and multivariate logistic regression ana-
lyses. As shown in Table 3, smoking (OR 5 2.55; 95% CI, 1.50–
4.35; p , 0.01) and alcohol (OR 5 2.64; 95% CI, 1.56–4.47; p ,
0.01) were associated with an increased risk of gastric cancer in
patients compared with controls based upon unconditional
univariate logistic regression analysis. The associations between
GC and seropositivity of NapA antibody were significant with OR
(95% CI) of 9.21 (1.96–43.14) while controlling for age, sex, smoking
and alcohol drinking (P , 0.01).
Screening utility of serum NapA antibody to GC. The receiver
operating characteristic (ROC) curve was plotted to evaluate the
screening utility and identify a cut-off point of serum NapA anti-
body result, as its value was considered as an independent predictor
of GC among the H. pylori-positive population. According to the
ROC curve, the optimal cutoff value for GC was 0.146, providing a
sensitivity of 86.36% and a specificity of 35.00%. When the NapA
cutoff value (OD) was 0.201, the sensitivity of serum NapA antibody
was 97.73% and specificity was 10.00%. With the cutoff value set at
0.065, the corresponding sensitivity and specificity were 15.15% and
95.00%, respectively (Table 4). The area under the receiver operating
characteristic curve (AUC) for NapA was 0.63 (95%CI, 0.56–0.70;
Supplementary Fig. S3).
Discussion
Helicobacter pylori infection has been established as a major risk
factor for gastric cancer, and the World Health Organization clas-
sified H. pylori infection as a definite (class I) carcinogen in 19942,15.
Previous studies have confirmed that the incidence of gastric cancer
could be decreased by eradication of H. pylori infection16. The pre-
vention of gastric cancer by H. pylori eradication in healthy subjects
is conducted around the world. For example, a large-scale interven-
tion study of H. pylori eradication on gastric cancer prevention had
been conducted inChina17. The study included 1,630 patients withH.
pylori infection and followed up for 7.5 years. A prophylaxis effect of
H. pylori eradication for gastric cancer was observed16. In addition,
while screening by endoscopy or photofluorography is currently
employed in high-incidence populations, testing of serum biomar-
kers for H. pylori will provide a more convenient, cost-effective and
noninvasive screening method that can be practiced worldwide.
Many investigators and clinicians have therefore sought to find
accurate and sensitive noninvasive serum markers against H. pylori
related gastric cancer, but this remedy has yet to be found. Novel
serum markers are thus urgently required to identify ways to screen
H. pylori infection for eradication and prevent gastric cancer
formation.
In this paper, the seropositivity of H. pylori in 232 cases with
gastric cancer was significantly higher compared with 268 controls
Table 1 | Demographic characteristics and H. pylori detection results of subjects
Variables
Case (n 5 232) Control (n 5 268)
P*No. % No. %
Age (years, Mean 6 SD) 59.56 6 10.59 57.74 6 10.57 0.055
Sex 0.055
Female 58 25.00 88 32.84
Male 174 75.00 180 67.16
H. pylori serostatus 0.025
Positive 132 59.73 120 48.00
Negative 89 40.27 130 52.00
Equivocala 11 - 18 -
*P value was obtained from x2 test.
aEquivocal values were not calculated in our study.
www.nature.com/scientificreports
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determined using an ELISA. This confirmed that H. pylori infection
increased the risk of gastric cancer, which was in line with pre-
vious studies2,18. It has been reported that prevalence of H. pylori
was previously high in China but has been declining over recent
decades, varying by geographic locations. For the control group,
seropositivity of H. pylori was 48.00%, which was lower than that
in Muping (50.95%), but higher than that in Yanqing (41.35%)19.
For the GC patients, seropositivity of H. pylori was 59.73%, which
was close to that in Taiwan (60.9%)20 and German (66.1%)21, but
higher than that in Greece (34.9%)22, and lower than that in Japan
(82.0%)23. However, the prevalence of H. pylori infection might be
underestimated due to disease-related clearance of H. pylori infec-
tion in the past or the spontaneous disappearance of the bac-
terium from the gastric mucosa during the progression of
gastric atrophy precancerous lesions24. It should be noticed that
seropositivity of H. pylori in a hospital-based case-control study
cannot reflect the accurate H. pylori prevalence in the population.
Although it can reflect the H. pylori prevalence to some extent, we
should be careful to compare the results to those from population-
based studies.
Table 2 | NapA antibodies levels and clinicopathological factors of the H. pylori-infected individuals
Variables
Case (n 5 132) Control (n 5 120)
No. % No. %
NapA antibodies levels
Range 0.03–0.65 0.05–0.32
Mean 6 SD 0.11 6 0.07 0.13 6 0.05
Median 0.11 0.12
Smoking status
Ever/current 81 61.36 54 45.00
Never 37 28.03 63 52.50
Unknowna 14 10.61 3 2.50
Alcohol consumption
Ever/current 71 53.79 42 35.00
Never 48 36.36 75 62.50
Unknowna 13 9.85 3 2.50
Family history of gastric cancer
Yes 10 7.58
No 106 80.30
Unknowna 16 12.12
Tumor location
No-cardia 223 96.1
Cardia 9 3.9
Clinical stage
I 14 7.22
II 16 8.25
III 143 73.71
IV 21 10.82
Tumor size
T1 17 9.24
T2 12 6.52
T3 15 8.15
T4 140 76.09
Lymph node status
N0 68 37.78
N1 28 15.56
N2 29 16.11
N3 55 30.55
Distant metastasis
M0 179 89.50
M1 21 10.50
aInformation was not available.
Table 3 | Univariate and Multivariate models to detect potential risk factors for gastric cancer in subjects infected by H. pylori
Factors
Univariate Multivariate
OR 95% CI P* OR 95% CI P*
Age (,60 vs. $60) 1.58 0.94–2.64 0.08 1.70 0.95–3.02 0.07
Sex (male vs. female) 1.34 0.77–2.32 0.30 0.56 0.26–1.20 0.14
Smoking status (yes vs. no) 2.55 1.50–4.35 ,0.01 2.47 1.27–4.80 ,0.01
Alcohol consumption (yes vs. no) 2.64 1.56–4.47 ,0.01 2.42 1.24–4.72 ,0.01
NapA status (positive vs. negative) 8.14 1.83–36.19 ,0.01 9.21 1.96–43.14 ,0.01
*P value was obtained from unconditional logistic regression.
www.nature.com/scientificreports
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What’s more, accumulating evidence has indicated that H. pylori
infection could increase the risk of gastric non-cardia cancer but was
not or even inversely associated with the risk of gastric cardia can-
cer25,26. Our study included 9 (3.9%) gastric cardia cancer cases; how-
ever, their involvement did not affect the overall results and
conclusion.
In the present study, we explored the significance and the pro-
cesses of NapA, a virulence factor ofH. pylori, as a serum biomarker
in gastric cancer.
We cloned and expressed HP-NapA, which was then used as an
antigen to detect HP-NapA-specific antibodies in serum samples.
The levels of HP-NapA antibodies were detected in 132 H. pylori-
infected gastric cancer patients and 120 control subjects. As a result,
the unadjusted seropositivity of HP-NapA in patients was signifi-
cantly higher than in controls. Moreover, after adjustment for age,
gender, alcohol consumption and smoking history, seropositivity
remained significant. Although a significant difference was found
for the seropositivity of HP-NapA antibody in the two groups, the
median of HP-NapA antibody levels was only slightly lower in
patients than the controls (0.11 vs 0.12), which indicates high anti-
body titer HP-NapA may protect from the development of gastric
cancer.
An AUC value between 0.5–0.7 is considered as lower accuracy,
0.7–0.9 with certain accuracy, and greater than 0.9 with high accu-
racy. In our study, the AUC was 0.63. These suggests that although
NapA can be used as a serum biomarker for the screening ofH. pylori
infection, NapA does not seem to be an independent biomarker for
detecting high risk populations from H. pylori-infected individuals
who are susceptible to gastric cancer development.
On the other hand, Kountouras J et al. found that NapA was
potentially correlated with gastric carcinogenesis, but failed to estab-
lish any significance between the level of serum NapA antibody and
gastric cancer27,28. Recently, Choli-Papadopoulou et al. reported the
development of new drugs targetingH. pyloriNapA27,28. Our findings
were in line with a study conducted by Min Long et al. who found
significant correlation between serum NapA antibodies level in H.
pylori-infected patients and healthy controls29,30. They showed the
seropositivity for HP-NapA specific antibodies in gastric cancer
patients was higher than that in chronic gastritis patients and healthy
controls. However, multivariate analysis was not performed comple-
tely in their study, and thus it was unknown if confounding factors,
such as gender and smoking, contributed to the differences observed.
Moreover, the sample size was small (n 5 188, including cases and
controls) and the seropositivity for antibodies against HP-NapA in
gastric cancer was remarkably higher (97.7%).
NapA as an important virulence factor of H. pylori increases the
adhesion of neutrophils to endothelial cells. The significant relation-
ship between NapA antibody level and gastric cancer risk suggests
that NapA forebodes a substantial down-regulation effect in the
development of gastric cancer and HP-NapA low antibody titer pre-
dicts susceptibility to gastric cancer. However, the lowAUC indicates
thatNapA cannot be used as an independent screening and diagnosis
criterion of gastric cancer. It may be used in conjunction with other
assays for H. pylori screening and early detection for gastric cancer.
Other virulence factors of H. pylori such as CagA or VacA were not
evaluated at the same time with NapA as parallel comparisons were a
limitation to this study. More prospective studies should be carried
out with larger sample sizes to identify the ideal, inexpensive and
readily available biological markers for gastric cancer. Further
investigations are needed to evaluate the feasibility of NapA antibody
as a biomarker in population-based screening for gastric cancer.
Methods
Subjects.A case-control study was designed to evaluate the significance of NapA as a
biomarker for gastric cancer. This study included 232 gastric cancer patients (58
women and 174 men, ages 33–83, Table 1) who were newly diagnosed by the Third
Affiliated Hospital of Harbin Medical University between March-July, 2010. The
control group consisted of 184 healthy physical examination individuals and 84
cancer-free neurological patients, respectively (88 women and 180 men, ages 35–82,
Table 1). Moreover, all participants completed a face-to-face questionnaire regarding
sociodemographic characteristics, health status, lifestyle factors et al. Questionnaires
were recorded by two investigators independently. In addition, informed consent was
obtained from all participants and all procedures were carried out in accordance with
the guidelines by the Human Research and Ethics Committee of Harbin Medical
University. For standardization of the study all blood samples were collected by the
same venipuncture staff, each in 5 mL vacutainer tubes containing EDTA as an
anticoagulant. All blood samples were centrifuged and stored at280uC until assayed.
Cloning and purification of HP-NapA.A clinical strain ofH. pylori, isolated from a
gastric cancer patient at the Second Affiliated Hospital of Harbin Medical University,
was used and provisionally named HLJ016 by our group. Genomic DNA of HLJ016
was extracted using a DNA extraction kit (QIAGEN, USA) and stored at 280uC. The
extracted genomic DNA was then used as a template for amplification of the napA
coding region using a Taq DNA polymerase PCR kit (Takara, Biotechnology of
DALIAN). Two primer sequences corresponding to the 59 and 39 ends of the coding
gene30, including EcoR I and Xho I restriction sites. The PCR product was cloned into
the cloning vector pMD18-T and then transformed into E.coli strain DH5a. The
positive clones were screened by PCR and restriction enzyme digestion. DNA
sequence of the amplified napA gene was assayed after sequenced by using the
dideoxy chain termination method (biotechnology firm, BGI) then cloned into the
expression vector pGEX-4T-1. The recombinant plasmid napA/pGEX-4T-1 was then
transformed into E.coli BL21DE3 cells, confirmed by PCR and the same restriction
enzyme digestion, and the target DNA sequence of napA gene was assayed again
using the same method. The recombinant strain pGEX-4T-1-napA-BL21DE3 was
cultured in LBmediumwith 100 mg/mL ampicillin, and then induced by IPTGwith a
final concentration of 0.5 mmol/L at 25uC. E.coli cells were harvested after 6 hours
and lysed via ultrasonication. The suspension was collected and examined by 15%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The
recombinant protein was purified with GST affinity resin (GENMED SCIENTIFICS
INC, USA).
Serologic tests of theH. pylori by ELISA.A serologic test forH. pylori IgG antibodies
was run in duplicate using an enzyme immunoassay kit (IBL, German). Sensitivity
and specificity of the kit, given by the manufacturer, were all greater than 95%.
According to the manufacturer’s instruction, 101-fold diluted serum was measured,
with,8 units/ml considered as negative, 8–12 units/ml as equivocal, and.12 units/
ml as positive.
Detection of antibodies against HP-NapA in serum with ELISA. An ELISA was
performed according to previously published documents using prepared and purified
recombinant HP-NapA31–34. Briefly, the purified NapA protein was diluted to 4 mg/
ml and incubated overnight at 4uC. Plates were then washed five times with a PBS
Table 4 | Validity and positive predictive values for different NapA critical values in subjects classified as H. pylori-positive
Percentile1
NapA critical
value (OD)
Sensitivity (%) case test1/(case
test1 1 case test2)
Specificity (%) control test2/(control
test1 1 control test2)
Optimal cut-off point2 0.146 86.36 35.00
90% 0.201 97.73 10.00
75% 0.159 89.39 24.17
50% 0.121 62.88 49.17
25% 0.100 41.67 74.17
10% 0.077 24.24 89.17
5% 0.065 15.15 95.00
1Percentiles of serum NapA antibody levels in controls.
2Identification of the optimal cut-off point in the different parameters was performed according to the maximum Youden’s index (sensitivity 1 specificity 2 1).
www.nature.com/scientificreports
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buffer and blocked with 7% goat serum (AR0009, BOSTER) and incubated in a moist
chamber for 2 h at 37uC. Plates were again washed five times, each time for 3minutes.
300 mL/well with buffer, serum samples (1550) from patients or control individuals,
were then added to the microtiter wells, and the plates were incubated at 37uC for
60 min. After washing with PBS, 100 mL Peroxidase-Conjugated Goat Anti-Human
IgG (ZB-2304, ZSGB-BIO), diluted 1540,000 in buffer, was added to each well and
incubated for 60 min at 37uC. The plates were washed with PBS and TMB substrate
(100 mL) was added to the wells and incubated at room temperature for 15 min, free
of light. The reaction was terminated by adding 50 mL of stop solution. The
absorbance of each well was read at 450 nm using a microplate reader (BioTek
Synergy2, USA). Samples with absorbance OD#mean - 2 standard deviations (SDs)
of controls who infected by H. pylori were considered positive.
Statistical analysis. SPSS version 18.0 was used for all statistical analysis.
Distributions of variables and rates of H. pylori and NapA antibody were computed.
The p value,0.05 was used to determine the difference of rates among the groups of
gastric cancer and controls. Unconditional univariate and multivariate logistic
regression analyses were used to estimate OR and 95% CI for the relation in gastric
cancer and NapA antibody considering the potential confounders in H. pylori
infected individuals. Means, medians, and full ranges ofH. pylori and NapA antibody
levels of cases and controls were computed and compared with parametric test. ELISA
data were transformed by a logarithm function firstly, and then tested by the K-S Test.
Cut-off point was determined according to the mean - 2 standard deviations (SDs) of
controls who infected byH. pylori. Additionally, sensitivity, specificity and area under
the receiver operating characteristic curve (AUC) with 95% confidence intervals (CI)
were computed to evaluate the value of serum NapA antibody levels for screening
high risk population prone to gastric cancer.
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